<DOC>
	<DOCNO>NCT00333047</DOCNO>
	<brief_summary>Therapeutic intervention patient metastatic breast cancer aim prolong survival improve quality life . The objective trial ass initial chemotherapy follow endocrine therapy lead long disease-free interval compare chemotherapy alone .</brief_summary>
	<brief_title>Letrozole Metastatic Breast Cancer Combination With Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Inclusion criterion Histologically proven metastatic breast cancer Measurable disease , patient bone disease eligible Age ≥ 65 year Performance status ≤ 2 ( World Health Organization ) Estimated life expectancy therapy least 3 month Estrogen/progesteronereceptor status positive unknown Signed inform consent Exclusion criterion Prior chemo hormone therapy metastatic breast cancer ; prior therapy aromatase inhibitor adjuvant set Diseasefree interval adjuvant therapy &lt; 1 year Clinical sign central nervous system metastases Renal , bone marrow , liver insufficiency Severe coronary heart disease , cardiac insufficiency severe concomitant internal disease Pulmonary fibrosis/alveolitis Additional protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Metastatic breast cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Letrozole</keyword>
</DOC>